Drugs that contain Dalbavancin Hydrochloride

1. List of Dalvance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(9 months from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
Dec, 2023

(10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

NCE-1 date: May, 2023

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in